vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and First Foundation Inc. (FFWM). Click either name above to swap in a different company.
First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -97.9%, a 77.9% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 421.7%). First Foundation Inc. produced more free cash flow last quarter ($-35.2M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -2.7%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
ABCL vs FFWM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $48.4M |
| Net Profit | $-8.9M | $-8.0M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | -97.5% |
| Net Margin | -19.9% | -97.9% |
| Revenue YoY | 788.4% | 421.7% |
| Net Profit YoY | 73.9% | 43.0% |
| EPS (diluted) | $-0.03 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $48.4M | ||
| Q3 25 | $9.0M | $63.6M | ||
| Q2 25 | $17.1M | $51.4M | ||
| Q1 25 | $4.2M | $71.4M | ||
| Q4 24 | $5.0M | $9.3M | ||
| Q3 24 | $6.5M | $9.2M | ||
| Q2 24 | $7.3M | $57.5M | ||
| Q1 24 | $10.0M | $51.1M |
| Q4 25 | $-8.9M | $-8.0M | ||
| Q3 25 | $-57.1M | $-146.3M | ||
| Q2 25 | $-34.7M | $-7.7M | ||
| Q1 25 | $-45.6M | $6.9M | ||
| Q4 24 | — | $-14.1M | ||
| Q3 24 | $-51.1M | $-82.2M | ||
| Q2 24 | $-36.9M | $3.1M | ||
| Q1 24 | $-40.6M | $793.0K |
| Q4 25 | -63.7% | -97.5% | ||
| Q3 25 | -851.8% | -92.7% | ||
| Q2 25 | -290.2% | -21.1% | ||
| Q1 25 | -1479.6% | 8.8% | ||
| Q4 24 | — | -247.7% | ||
| Q3 24 | -1439.4% | -1276.7% | ||
| Q2 24 | -1276.2% | 4.6% | ||
| Q1 24 | -551.5% | -0.2% |
| Q4 25 | -19.9% | -97.9% | ||
| Q3 25 | -637.8% | -230.1% | ||
| Q2 25 | -203.3% | -15.0% | ||
| Q1 25 | -1077.2% | 9.7% | ||
| Q4 24 | — | -152.2% | ||
| Q3 24 | -785.4% | -896.9% | ||
| Q2 24 | -504.3% | 5.4% | ||
| Q1 24 | -408.0% | 1.6% |
| Q4 25 | $-0.03 | $-0.09 | ||
| Q3 25 | $-0.19 | $-1.78 | ||
| Q2 25 | $-0.12 | $-0.09 | ||
| Q1 25 | $-0.15 | $0.08 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | $-0.17 | $-1.23 | ||
| Q2 24 | $-0.13 | $0.05 | ||
| Q1 24 | $-0.14 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $1.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $912.6M |
| Total Assets | $1.4B | $11.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $1.6B | ||
| Q3 25 | $83.2M | $1.7B | ||
| Q2 25 | $92.4M | $1.1B | ||
| Q1 25 | $159.3M | $1.0B | ||
| Q4 24 | $156.3M | $1.0B | ||
| Q3 24 | $126.6M | $1.1B | ||
| Q2 24 | $148.3M | $1.4B | ||
| Q1 24 | $123.6M | $1.6B |
| Q4 25 | $966.9M | $912.6M | ||
| Q3 25 | $964.0M | $917.9M | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.1B | $933.2M | ||
| Q1 24 | $1.1B | $928.7M |
| Q4 25 | $1.4B | $11.9B | ||
| Q3 25 | $1.4B | $11.9B | ||
| Q2 25 | $1.4B | $11.6B | ||
| Q1 25 | $1.3B | $12.6B | ||
| Q4 24 | $1.4B | $12.6B | ||
| Q3 24 | $1.4B | $13.4B | ||
| Q2 24 | $1.4B | $13.7B | ||
| Q1 24 | $1.5B | $13.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-31.9M |
| Free Cash FlowOCF − Capex | $-44.6M | $-35.2M |
| FCF MarginFCF / Revenue | -99.4% | -72.8% |
| Capex IntensityCapex / Revenue | 21.9% | 6.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-45.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $-31.9M | ||
| Q3 25 | $-52.6M | $9.2M | ||
| Q2 25 | $-32.4M | $-16.3M | ||
| Q1 25 | $-11.6M | $-552.0K | ||
| Q4 24 | $-108.6M | $-8.7M | ||
| Q3 24 | $-28.9M | $14.2M | ||
| Q2 24 | $-30.0M | $-9.1M | ||
| Q1 24 | $-41.7M | $7.2M |
| Q4 25 | $-44.6M | $-35.2M | ||
| Q3 25 | $-61.5M | $8.6M | ||
| Q2 25 | $-45.8M | $-16.7M | ||
| Q1 25 | $-22.2M | $-2.5M | ||
| Q4 24 | $-187.0M | $-11.4M | ||
| Q3 24 | $-47.4M | $13.4M | ||
| Q2 24 | $-50.1M | $-9.4M | ||
| Q1 24 | $-65.8M | $5.9M |
| Q4 25 | -99.4% | -72.8% | ||
| Q3 25 | -687.0% | 13.5% | ||
| Q2 25 | -267.9% | -32.4% | ||
| Q1 25 | -524.0% | -3.5% | ||
| Q4 24 | -3702.8% | -123.5% | ||
| Q3 24 | -728.4% | 146.2% | ||
| Q2 24 | -683.8% | -16.3% | ||
| Q1 24 | -661.5% | 11.6% |
| Q4 25 | 21.9% | 6.9% | ||
| Q3 25 | 99.7% | 1.0% | ||
| Q2 25 | 78.2% | 0.8% | ||
| Q1 25 | 251.1% | 2.8% | ||
| Q4 24 | 1552.7% | 29.4% | ||
| Q3 24 | 284.6% | 9.0% | ||
| Q2 24 | 274.6% | 0.4% | ||
| Q1 24 | 242.5% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.96× | ||
| Q1 24 | — | 9.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
